Home  /  Resource Library  /  Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a Phase Ib/II Trial

Polatuzumab Vedotin Plus Obinutuzumab and Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma: Primary Analysis of the Full Efficacy Population in a Phase Ib/II Trial

ASH 2019: Results of a study examining the combination of Polatuzumab Vedotin combined with Obinutuzumab and Lenalidomide for treatment of relapsed follicular lymphoma.